Formosa Biomedical Technology Corp. Announces Board Approval of Q1 2026 Financial Report
Key facts
- Formosa Biomedical Technology Corp. Announces Board Approval of Q1 2026 Financial Report
- Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
- Source: PR Times
- Date: May 8, 2026
Direct answer
Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
- Citation
- Formosa Biomedical Technology Corp. Announces Board Approval of Q1 2026 Financial Report (May 8, 2026), PR Times
- Source
- PR Times
- Date
- May 8, 2026
Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
📋 Article Processing Timeline
- 📰 Published: May 8, 2026 at 09:00
- 🔍 Collected: May 9, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 9, 2026 at 09:39 (1h 39m after Collected)
2. Date of approval by the audit committee: 2026/04/28
3. Reporting period of financial report or self-audited financial information
Start and end dates (YYYY/MM/DD~YYYY/MM/DD): 2026/01/01~2026/03/31
4. Cumulative operating revenue from January 1st to the end of this period (in thousands): 1,391
5. Cumulative operating gross profit (gross loss) from January 1st to the end of this period (in thousands): 1,042
6. Cumulative operating profit (loss) from January 1st to the end of this period (in thousands): (50,802)
7. Cumulative pre-tax net profit (net loss) from January 1st to the end of this period (in thousands): (46,308)
8. Cumulative net profit (net loss) for this period from January 1st to the end of this period (in thousands): (46,308)
9. Cumulative net profit (loss) attributable to owners of parent company from January 1st to the end of this period (in thousands): (46,308)
10. Cumulative basic earnings (loss) per share from January 1st to the end of this period (in dollars): (0.53)
11. Total assets at the end of the period (in thousands): 883,757
12. Total liabilities at the end of the period (in thousands): 34,684
13. Equity attributable to owners of parent company at the end of the period (in thousands): 849,073
14. Other matters that need to be specified: None.
FAQ
What are the key facts in this article?
Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
What is the direct answer?
Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.
What is the source and date?
PR Times: https://mops.twse.com.tw/material/twse-6657-2026-05-08-455750fa | May 8, 2026